Fluidigm sees Q4 revenue approximately $21M, consensus $19.53M Instrument revenue is expected to be approximately $12M and consumables revenue is expected to be approximately $8.5M. Fluidigm’s instrument installed base increased to approximately 920 units at the end of Q4.
Fluidigm shares offer attractive entry point, says Leerink Leerink believes the current share of Fluidigm represents an attractive entry point ahead of the company's new product launches. The firm thinks Fluidigm is well positioned to benefit from the growth in single cell analysis. It keeps an Outperform rating on the name with a $45 price target.
Fluidigm downgraded to Neutral from Buy at Mizuho Mizuho analyst Peter Lawson downgraded Fluidigm to Neutral citing a lack of visibility and increased revenue volatility following the company's weaker than expected Q1 results. Lawson cut his price target for shares to $30 from $50.